You are here: Home 
Categories Prostate Cancer
Categories Prostate Cancer Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone - Abstract
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone - Abstract
Published on 17 August 2012
BACKGROUND: Endothelin-1 and the endothelin A (ETA ) receptor have been implicated in prostate cancer progression in bone.
To read more, a FREE Urotoday registration is required. Click here to register or login above.To read UIJ content, a separate subscription is required.
Tags:
